Article Information
History
- February 2, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Paula de Michelena1,†,
- Ignacio Torres1,†,
- Ángela Ramos-García2,
- Victoria Gosalbes3,
- Nidia Ruiz4,
- Ana Sanmartín5,
- Pilar Botija5,
- Sandrine Poujois1,
- Dixie Huntley1,
- Eliseo Albert1 and
- David Navarro1,6,*
- 1Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
- 2Health Care center Benimaclet, Health Department Clínico-Malvarrosa, Valencia, Spain
- 3Health Care center Salvador Pau, Health Department Clínico-Malvarrosa, Valencia, Spain
- 4Health Care center Serrería, Health Department Clínico-Malvarrosa, Valencia, Spain
- 5Primary Health Directorate, Health Department Clínico-Malvarrosa, Valencia, Spain
- 6Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain
- ↵*Correspondence:
David Navarro, Microbiology Service, Hospital Clínico Universitario, Instituto de Investigación INCLIVA. Av. Blasco Ibáñez 17, 46010 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; Email: david.navarro{at}uv.es.
↵† Both authors contributed equally to the present work.
Posted February 02, 2022.
Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant
